Literature DB >> 29026593

Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients.

Hideki Mori1,2, Hidekazu Suzuki3, Juntaro Matsuzaki1,4, Tatsuhiro Masaoka1, Takanori Kanai1.   

Abstract

BACKGROUND AND AIM: Helicobacter pylori (H. pylori) eradication regimen has not been standardized for patients with penicillin allergy. We investigated the association between the efficacy of a 10-day sitafloxacin, metronidazole, and esomeprazole triple regimen and antibiotic resistance, in patients with penicillin allergy.
METHODS: Penicillin-allergic patients infected with H. pylori were enrolled between March 2014 and November 2015. The minimum inhibitory concentrations (MICs) of sitafloxacin and metronidazole, and the gyrA mutation status of the H. pylori strains were determined before treatment. The cut-off points for antimicrobial resistance were defined as 8.0 µg/ml for metronidazole and 0.12 µg/ml for sitafloxacin. The patients received the triple therapy (20 mg esomeprazole, bid; 250 mg metronidazole, bid; and 100 mg sitafloxacin, bid) for 10 days. Successful eradication was evaluated using the [13C] urea breath test or the H. pylori stool antigen test.
RESULTS: Fifty-seven patients were analyzed, and the overall eradication rate was 89.5%. The eradication rate in cases of double antibiotic resistance to metronidazole and sitafloxacin was 40.0%, whereas for other combinations of resistance, this was above 90.0%. Finally, the eradication rate of gyrA mutation-negative strains was 96.2%, whereas for gyrA mutation-positive strains, it was 83.9%. Adverse events were reported in 31.6% of cases, all of which were mild and tolerable.
CONCLUSION: Ten days of sitafloxacin and metronidazole triple therapy was safe and highly effective in eradicating H. pylori in penicillin-allergic patients. Double resistance to metronidazole and sitafloxacin was an important predicting factor for eradication failure. However, 10 days of the sitafloxacin and metronidazole triple therapy was highly effective if the strain was susceptible to either sitafloxacin or metronidazole.

Entities:  

Keywords:  Sitafloxacin; gyrA; metronidazole; penicillin allergy

Year:  2017        PMID: 29026593      PMCID: PMC5625875          DOI: 10.1177/2050640616688995

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  27 in total

1.  Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.

Authors:  Jyh-Ming Liou; Chi-Yang Chang; Wang-Huei Sheng; Yu-Chi Wang; Mei-Jyh Chen; Yi-Chia Lee; Hsu-Wei Hung; Hung Chian; San-Chun Chang; Ming-Shiang Wu; Jaw-Town Lin
Journal:  Antimicrob Agents Chemother       Date:  2010-12-28       Impact factor: 5.191

Review 2.  Helicobacter pylori eradication therapy.

Authors:  Hidekazu Suzuki; Toshihiro Nishizawa; Toshifumi Hibi
Journal:  Future Microbiol       Date:  2010-04       Impact factor: 3.165

3.  Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin.

Authors:  Takahisa Furuta; Mitsushige Sugimoto; Mihoko Yamade; Takahiro Uotani; Shu Sahara; Hitomi Ichikawa; Takuma Kagami; Takanori Yamada; Satoshi Osawa; Ken Sugimoto; Hiroshi Watanabe; Kazuo Umemura
Journal:  Intern Med       Date:  2014       Impact factor: 1.271

4.  Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.

Authors:  Toshihiro Nishizawa; Hidekazu Suzuki; Kumiko Kurabayashi; Tatsuhiro Masaoka; Hiroe Muraoka; Mikiji Mori; Eisuke Iwasaki; Intetsu Kobayashi; Toshifumi Hibi
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

5.  High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin.

Authors:  Maribel Rodríguez-Torres; Rosa Salgado-Mercado; Carlos F Ríos-Bedoya; Edgardo Aponte-Rivera; Acisclo M Marxuach-Cuétara; José F Rodríguez-Orengo; Alberto Fernández-Carbia
Journal:  Dig Dis Sci       Date:  2005-04       Impact factor: 3.199

6.  Homology model of the DNA gyrase enzyme of Helicobacter pylori, a target of quinolone-based eradication therapy.

Authors:  Juntaro Matsuzaki; Hidekazu Suzuki; Hitoshi Tsugawa; Toshihiro Nishizawa; Toshifumi Hibi
Journal:  J Gastroenterol Hepatol       Date:  2010-05       Impact factor: 4.029

7.  Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group).

Authors:  Takashi Kawai; Shin'ichi Takahashi; Hidekazu Suzuki; Hitoshi Sasaki; Akihito Nagahara; Daisuke Asaoka; Takeshi Matsuhisa; Tatsuhiro Masaoaka; Toshihiro Nishizawa; Masayuki Suzuki; Masayoshi Ito; Naoto Kurihara; Fumio Omata; Shigeaki Mizuno; Akira Torii; Kohei Kawakami; Toshifumi Ohkusa; Kengo Tokunaga; Tetsuya Mine; Nobuhiro Sakaki
Journal:  J Gastroenterol Hepatol       Date:  2014-12       Impact factor: 4.029

8.  Diagnosis of Helicobacter pylori infection with a new non-invasive antigen-based assay. HpSA European study group.

Authors:  D Vaira; P Malfertheiner; F Mégraud; A T Axon; M Deltenre; A M Hirschl; G Gasbarrini; C O'Morain; J M Garcia; M Quina; G N Tytgat
Journal:  Lancet       Date:  1999-07-03       Impact factor: 79.321

9.  In vitro activity of fluoroquinolone and the gyrA gene mutation in Helicobacter pylori strains isolated from children.

Authors:  Shigeru Fujimura; Seiichi Kato; Kazuie Iinuma; Akira Watanabe
Journal:  J Med Microbiol       Date:  2004-10       Impact factor: 2.472

Review 10.  Clinical studies of 13C-urea breath test in Japan.

Authors:  M Kato; M Asaka; S Ohara; T Toyota
Journal:  J Gastroenterol       Date:  1998       Impact factor: 7.527

View more
  6 in total

1.  Reply to the letter to the editor: H. pylori test-and-treat should not be put off for gastric cancer prevention in East Asia any longer.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  J Gastroenterol       Date:  2018-06       Impact factor: 7.527

Review 2.  Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.

Authors:  Evariste Tshibangu-Kabamba; Yoshio Yamaoka
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-17       Impact factor: 46.802

3.  Effective therapeutic regimens in two South Asian countries with high resistance to major Helicobacter pylori antibiotics.

Authors:  Muhammad Miftahussurur; Hafeza Aftab; Pradeep Krishna Shrestha; Rabi Prakash Sharma; Phawinee Subsomwong; Langgeng Agung Waskito; Dalla Doohan; Kartika Afrida Fauzia; Yoshio Yamaoka
Journal:  Antimicrob Resist Infect Control       Date:  2019-02-15       Impact factor: 4.887

Review 4.  Treatment of Helicobacter pylori infection in the presence of penicillin allergy.

Authors:  Amit Kumar Dutta; Perminder Singh Phull
Journal:  World J Gastroenterol       Date:  2021-11-28       Impact factor: 5.742

Review 5.  Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones.

Authors:  Javier P Gisbert
Journal:  Molecules       Date:  2020-11-02       Impact factor: 4.411

6.  Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens.

Authors:  Hideki Mori; Hidekazu Suzuki; Juntaro Matsuzaki; Tatsuhiro Masaoka; Takanori Kanai
Journal:  United European Gastroenterol J       Date:  2017-10-08       Impact factor: 4.623

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.